TMO · Thermo Fisher Scientific, Inc.

The thesis

Thermo Fisher Scientific's biopharma services growth carried a beat-and-raise third quarter, and a new $5 billion buyback authorization on 5 November 2026 extends support for per-share earnings. Fourth-quarter results and the first 2027 guidance, expected around 28 January 2027, settle whether that pace lasts. The company's own fourth-quarter outlook of 4% organic growth already points to slower growth.

On 21 October 2026 the company reported third-quarter revenue of $12.14 billion, up 9%, with 6% organic growth. Organic growth excludes acquisitions, divestitures and currency. Management raised 2026 guidance to revenue of $47.7–$48.2 billion and adjusted EPS of $25.13–$25.43.

The news since then is about capital, with no operating update. The board renewed the buyback on 5 November 2026, and the company issued 800 million Swiss francs of bonds, fiscal.ai reported on 2 November 2026. The narrative is maturing: at least eight brokers raised targets between 22 October 2026 and 30 October 2026, and company news shows no further raise since Argus on 30 October 2026. The shares closed at $676.94 on 5 November 2026, against $697.00 on 30 October 2026, and they need new business evidence to keep beating the index.

Bullish and bearish views on Thermo Fisher Scientific, Inc.

The bull case on Thermo Fisher Scientific, Inc. (TMO), in brief: Buyback capacity is back to $5 billion. The bear case: Fourth-quarter outlook stays at 4%.

Bull case

• Buyback capacity is back to $5 billion. The board authorized up to $5 billion of repurchases on 5 November 2026, with no expiration date, replacing an authorization with $1 billion remaining, according to the company's release. The company bought back $4.0 billion of stock in the first nine months of 2026, per its 21 October 2026 8-K.
• Biopharma services is the growth engine. Laboratory Products and Biopharma Services revenue was $6,863 million in the third quarter of 2026, the largest of the four segments, according to the 8-K. Chief Financial Officer Jim Meyer said on the 21 October 2026 call that second-half organic growth guidance rose to 5% from 4%.
• Margins and cash flow improved together. Adjusted operating margin reached 24.5% in the third quarter of 2026, up from 23.3% a year earlier. Year-to-date free cash flow was $4,618 million, up from $3,319 million, and full-year guidance rose to $7.0–$7.5 billion on 21 October 2026.
• Clario contributes earnings and a data business. The $8.875 billion cash acquisition of Clario, which supplies endpoint data for clinical trials, closed on 24 March 2026. The company expects it to contribute $0.45 of adjusted EPS in the first year after closing.
• Most broker targets sit above the shares. Citi raised its target to $800 from $685 on 23 October 2026, and Argus moved to $780 on 30 October 2026. TD Cowen's target is $810, set on 22 October 2026. All three sit above the $676.94 close on 5 November 2026.

Bear case

• Fourth-quarter outlook stays at 4%. Management kept fourth-quarter organic growth guidance at 4% on 21 October 2026, below the third quarter's 6%. The CFO said much of the pharma services strength fell in the third quarter because of the timing of customer activity.
• Part of the earnings beat was one-off. On the 21 October 2026 call, management attributed $0.15 of the EPS outperformance against prior guidance to tariff refunds. Operations contributed $0.08 and currency $0.03.
• One broker cut its target below the price. Evercore ISI lowered its target to $615 from $720 on 28 October 2026, fiscal.ai reported, which sits under the $676.94 close. RBC Capital kept a Sector Perform rating on 22 October 2026 with a $730 target.
• Specialty Diagnostics revenue shrank. The segment reported $1,098 million in third-quarter 2026 revenue, lower than a year earlier, according to the 8-K. The microbiology divestiture completed in the quarter accounts for part of that decline.
• The buyback renewal repeats last year's pattern. The board also authorized $5 billion on 6 November 2025, and $3.00 billion of it was spent early in the first quarter of 2026, according to the company's 2025 10-K. A similar authorization this year carries little new information about demand.

Price setup

The shares closed at $676.94 on 5 November 2026, 4.5% below the 52-week high of $709.18, on adjusted daily closes. The three-month gain stood at 13.0% on that date, against 23.5% at the $697.00 close on 30 October 2026. The 14-day relative strength index, a momentum gauge running from 0 to 100, was 45.9, so recent buying pressure has cooled.

Company news between those two closes covers a bond issue, a low-priced laboratory reagent launch and the buyback, and none of it changes operating guidance. The decline leaves the shares closer to the $650 invalidation level and further below most broker targets.

Crowding evidence is modest. Chief Human Resources Officer Lisa P. The company is repurchasing stock, and no equity issuance appears in company news. The next earnings report is about 12 weeks away.

Catalysts, next 30 days

• 10 November 2026: Thermo Fisher experts host a webinar on Clario endpoint data solutions. It is a minor read on the Clario business, with no financial update scheduled.
• ~28 January 2027, est.: Fourth-quarter 2026 report and first 2027 guidance, and the event the case turns on. The date is an estimate from last year's schedule: the company set its 29 January 2026 call in a release dated 26 December 2025. The comparison is fourth-quarter 2025 revenue of $12.21 billion and adjusted EPS of $6.57.

No earnings, guidance or regulatory event with a confirmed date falls in the next 30 days.

What would change the view

The case breaks if fourth-quarter organic growth comes in below the 4% guidance, or if initial 2027 organic growth guidance falls below the 2026 pace. Management citing lower biopharma services activity at that report would confirm the third quarter was a timing effect. Further EPS beats driven mainly by one-off items such as tariff refunds would also weaken it.

On price, a daily close below $650 would give back a further part of the rally around the 21 October 2026 report and end the thesis.

The case strengthens if fourth-quarter organic growth lands above 4% with operations, and no one-off item, driving the EPS beat. First 2027 guidance at or above the 2026 pace would extend it.

What it trades with

The shares respond most directly to spending by pharmaceutical and biotech customers, which drives the largest segment. Tariffs affect reported earnings, as the $0.15 refund effect in the third quarter of 2026 showed. Currency contributed $0.03 of the same outperformance, and the 2 November 2026 Swiss franc bonds extend the company's non-dollar debt. Those exposures are specific to this business, and the late-January report is the next event that tests them.